OTCMKTS:LHDXQ Lucira Health (LHDXQ) Stock Price, News & Analysis $0.0001 +0.00 (+∞) As of 10/4/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Lucira Health Stock (OTCMKTS:LHDXQ) Get Lucira Health alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.00▼$1.45Volume20,900 shsAverage Volume7.18 million shsMarket Capitalization$4.06 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lucira Health, Inc. is a developer of rapid molecular diagnostic tests designed for use in home and point-of-care settings. Headquartered in Emeryville, California, the company leverages proprietary reverse transcription–loop-mediated isothermal amplification (RT-LAMP) technology to deliver single-use, instrument-free assays. Its flagship product, the Lucira COVID-19 All-In-One Test Kit, enables users to collect a nasal swab sample, run the test on-site and obtain results in under 30 minutes without the need for a laboratory. In December 2020, Lucira Health received emergency use authorization (EUA) from the U.S. Food and Drug Administration for its COVID-19 test kit. The company rapidly expanded commercial availability through partnerships with national pharmacy chains, online retailers and direct-to-consumer channels, making at-home molecular testing broadly accessible across the United States. Lucira’s platform is inherently adaptable, and the company has signaled plans to pursue additional respiratory pathogen assays as regulatory approvals and market demand evolve. While primarily serving the North American market, Lucira Health has explored distribution opportunities in select international regions and continues to seek regulatory clearances abroad. The company’s management team draws on extensive experience in diagnostics, consumer health and medical device commercialization, underscoring its commitment to advancing accessible, high-performance testing solutions that reduce dependency on centralized laboratory infrastructure.AI Generated. May Contain Errors. Read More Receive LHDXQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucira Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LHDXQ Stock News HeadlinesHealthcare bankruptcies slow after peaking in 2023: reportAugust 24, 2024 | msn.comU.S. govt. to restart program to ship free at-home COVID testsSeptember 20, 2023 | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Best Senior Dating Sites Of 2023August 3, 2023 | forbes.comRemember Lucira Health's 30 Minute Home Test Kit? Pfizer Just Bought the Bankrupt Company Via Winning Auction BidApril 28, 2023 | benzinga.com8-K: Lucira Health, Inc.April 20, 2023 | marketwatch.comBankruptcy court bidder for Covid-flu test maker Lucira objects to planned sale to PfizerApril 11, 2023 | bizjournals.comPfizer to buy Covid-flu test developer Lucira Health out of bankruptcy courtApril 7, 2023 | bizjournals.comSee More Headlines LHDXQ Stock Analysis - Frequently Asked Questions How have LHDXQ shares performed this year? Lucira Health's stock was trading at $0.0001 at the beginning of the year. Since then, LHDXQ stock has increased by 0.0% and is now trading at $0.0001. How were Lucira Health's earnings last quarter? Lucira Health, Inc. (OTCMKTS:LHDXQ) issued its quarterly earnings data on Thursday, November, 11th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.04. The business had revenue of $14.98 million for the quarter, compared to the consensus estimate of $18 million. How do I buy shares of Lucira Health? Shares of LHDXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/11/2021Today9/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolOTCMKTS:LHDXQ CIK1652724 Webwww.lucirahealth.com Phone510-350-8071FaxN/AEmployees221Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$93.06 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.81 per share Price / Book0.00Miscellaneous Outstanding Shares40,600,000Free Float28,257,000Market Cap$4.06 thousand OptionableNot Optionable Beta2.60 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:LHDXQ) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucira Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucira Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.